Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | CA12 | O43570 | 3/20 | 0.62 |
| ▸ | CA9 | Q16790 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | F13A1 | P00488 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7103283 | 1.00 | RECQL (0.70) | RECQLCA12CA9TSHRMEN1 | |
| SCHEMBL635948 | 1.00 | RECQL (0.70) | RECQLCA12CA9TSHRMEN1 | |
| SCHEMBL8355313 | 1.00 | RECQL (0.70) | RECQLCA12CA9TSHRMEN1 | |
| SCHEMBL634179 | 1.00 | RECQL (0.70) | RECQLCA12CA9TSHRMEN1 | |
| SCHEMBL633647 | 1.00 | RECQL (0.70) | RECQLCA12CA9TSHRMEN1 | |
| SCHEMBL223155 | 1.00 | RECQL (0.70) | RECQLCA12CA9TSHRMEN1 | |
| SCHEMBL31664326 | 1.00 | RECQL (0.70) | RECQLCA12CA9TSHRMEN1 | |
| SCHEMBL635207 | 0.98 | RECQL (0.68) | RECQLCA12CA9TSHRMEN1 | |
| SCHEMBL635553 | 0.93 | CA12 (0.63) | RECQLCA12CA9TSHRMEN1 | |
| SCHEMBL31391062 | 0.93 | CA12 (0.63) | RECQLCA12CA9TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107743502-B | Curing composition | 爱客多有限公司 | 2020-08-28 | — | — | CN | disclosed |
| US-20200071310-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| US-20200071310-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| EP-3551621-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018109642-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018109642-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| EP-2302000-B1 | CURABLE COMPOSITION AND CATALYST COMPOSITION | KANEKA CORP (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-9051501-B2 | Curable composition and catalyst composition | KANEKA CORPORATION (JP) | 2015-06-09 | — | — | US | disclosed |
| EP-2100923-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2013-03-13 | — | — | EP | disclosed |
| EP-2088173-B1 | CURABLE COMPOSITION AND CATALYST COMPOSITION | KANEKA CORP (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-8008386-B2 | Curable composition | KANEKA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-2302000-A1 | Curable composition and catalyst composition | KANEKA CORPORATION (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20100063215-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100041810-A1 | CURABLE COMPOSITION AND CATALYST COMPOSITION | KANEKA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2100923-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2009-09-16 | — | — | EP | disclosed |
| EP-2088173-A1 | CURABLE COMPOSITION AND CATALYST COMPOSITION | Kaneka Corporation (JP) | 2009-08-12 | — | — | EP | disclosed |
| US-4053458-A | INHIBITORS | UOP INC. (US) | 1977-10-11 | — | — | US | disclosed |
| US-4022828-A | BIS-(SULFONAMIDO)-SULFIDES | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071310-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, NQO1, KEAP1 | RECQL 1532/4885CA12 4881/4885CA9 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.